Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KSHN001034 in Healthy Postmenopausal Women
NCT06995482Phase 1Recruiting
- Sponsor
- Kashiv BioSciences
- Start
- Aug 2025
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of KSHN001034 in Hormone-Receptor-Positive Breast Cancer (5 cohorts), sponsored by Kashiv BioSciences. Primary endpoint: Number of participants with treatment-related Adverse events at 36 days. Started Aug 2025; status: recruiting.
02
Drugs
KSHN001034
03
Conditions
Hormone-Receptor-Positive Breast Cancer
Beyond the preview
Go deeper on NCT06995482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06995482.